Drugs in the graveyard increase costs
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
What is Health Literacy?
Sometimes, when we think about a new app or technology that will be useful for improving health in African people, we don’t consider the applicability that this app will have.
The last two months HiTT has been working in 2 different projects of innovative public purchase, this week we finally have present them to the regional health service call.
Dr. Solà-Morales has been selected to become one of the professors that will teach in this postgraduate study provided by the IQS (Instituto Químico de Sarrià).
Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective.
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
Taking part in the XXXVII Jornadas de economia de la salud.